Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Evaluation of clinical benefit and progression-free survival ratio of targeted treatments in a prospective cohort study of patients with biliary tract cancers.
Authors
Monica Niger
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
Monica Niger , Federico Nichetti , Andrea Vingiani , Chiara Carlotta Pircher , Luca Agnelli , Elena Conca , Elena Tamborini , Federica Perrone , Eleonora Gusmaroli , Andrea Franza , Francesca Corti , Leonardo Provenzano , Federica Morano , Giancarlo Pruneri , Maria Di Bartolomeo , Filippo Pietrantonio , Filippo G. De Braud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 590)
DOI
10.1200/JCO.2023.41.4_suppl.590
Abstract #
590
Poster Bd #
F2
Abstract Disclosures
Similar Posters
First Author: Fabricio Racca
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterizing outcomes of ERBB2-amplified biliary tract cancer.
First Author: Daniel Aaron Fox
Poster
2023 ASCO Annual Meeting
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.
First Author: Subotheni Thavaneswaran
Poster
2021 ASCO Annual Meeting
Multimodal profiling of biliary tract cancers to detect potentially actionable biomarkers and differences in immune signatures between subtypes.
First Author: Kabir Mody